96847-54-0|Levomilnacipran|(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide|-范德生物科技公司

Levomilnacipran

NMR下载 COA and HPLC MSDS下载
names：
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
CAS号：
96847-54-0
MDL Number：
MF(分子式)： C15H22N2O MW(分子量)： 246.35
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Levomilnacipran
英文别名	Levomilnacipran; F2695; F 2695; F-2695
CAS号	96847-54-0
Inchi	InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1
InchiKey	GJJFMKBJSRMPLA-DZGCQCFKSA-N
分子式 Formula	C15H22N2O
分子量 Molecular Weight	246.35
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Levomilnacipran(CAS:96847-54-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Levomilnacipran is an antidepressant.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Chen L, Boinpally R, Gad N, Greenberg WM, Wangsa J, Periclou A, Ghahramani P. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. Clin Drug Investig. 2015 Oct;35(10):601-12. doi: 10.1007/s40261-015-0318-2. PubMed PMID: 26315684.

[2]Scott LJ. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder. CNS Drugs. 2014 Nov;28(11):1071-82. doi: 10.1007/s40263-014-0203-1. Review. PubMed PMID: 25270036.

[3] Brunner V, Maynadier B, Chen L, Roques L, Hude I, Séguier S, Barthe L, Hermann P. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Drug Des Devel Ther. 2015 Jun 23;9:3199-215. doi: 10.2147/DDDT.S80886. eCollection 2015. PubMed PMID: 26150694; PubMed Central PMCID: PMC4484650.

[4] Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014 Jan;39(1):40-9. doi: 10.1503/jpn.130040. PubMed PMID: 24144196; PubMed Central PMCID: PMC3868664.

[5] Hair P, Cameron F, Garnock-Jones KP. Levomilnacipran extended release: first global approval. Drugs. 2013 Sep;73(14):1639-45. doi: 10.1007/s40265-013-0116-1. Review. PubMed PMID: 24000002.

6: Mago R, Mahajan R, Thase ME. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Rev Clin Pharmacol. 2014 Mar;7(2):137-45. doi: 10.1586/17512433.2014.889563. Review. PubMed PMID: 24524592.7: Chen L, Greenberg WM, Gommoll C, O'Connor J, Zukin SR, Periclou A, Ghahramani P. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. Clin Ther. 2015 Sep;37(9):2059-70. doi: 10.1016/j.clinthera.2015.07.005. Epub 2015 Aug 20. PubMed PMID: 26256429.8: Saraceni MM, Venci JV, Gandhi MA. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. J Pharm Pract. 2014 Aug;27(4):389-95. doi: 10.1177/0897190013516504. Epub 2013 Dec 31. Review. PubMed PMID: 24381243.9: Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother. 2014 Aug;48(8):1030-1039. Epub 2014 May 8. Review. PubMed PMID: 24811398.10: Zaman S, McLaughlin MR. Levomilnacipran (Fetzima) for Major Depressive Disorder. Am Fam Physician. 2015 Oct 15;92(8):727-31. PubMed PMID: 26554414.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开